Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Boxes of tablets produced by Novartis AG, sit on a pharmacy meter.
Bloomberg | Bloomberg | Getty pictures
Pharmaceutical Firm in Swedish Novartis On Thursday, the next blockbuster drug in the portfolio of the cyclistic breast cancer treatment, the confidence awaits the next blockbuster medicine for heart failure therapy.
Kisgali, who treats the metrastatic breast cancer, increased by 64% on a global scale on a sustainable currency until June. This includes 100% increase in the United States
The first quarter increased by 56% in the sale of Kisgala until March.
Speaking about the call for profit, Kisgali was the largest drug above Kisgali, he said.
According to the World Health Organization, the diagnosis of global breast cancer and death is projected to increase in 2050 Cancer agencyIn 1 of the world’s 20 women, it is expected to be diagnosed with breast cancer throughout the life.
If current trends continue, in a total of 3.2 million new cases in 2050 and 3.2 million new cases and 1.1 million deaths a year, the research is 2.3 million new jobs and more than 670,000.
Narasimhan said that other drugs are “Blockbuster” for chronic myeloid lekemi, including the “strong pipeline”, including Novartis’s Novartis’s “powerful pipeline”.
“Kisgali, Pluvicto and Scemblix have added a statement that accompanies the results of the change in our portfolio and the powerfolio.
Novartis comes comments next year as the US patent’s patent ends the comments to enter the most sold entreso heart failure drug. Entresto brought $ 7.8 billion in 2024, which made about 15% of the company’s total global sales.
On Thursday, the general drug producers expected to start production of the medication by the mid-2025, then the schedule will be subject to the “IP (intellectual property) and the regulatory trial.
On Wednesday, the US refers to a request of Federal Judge Novartis Initial instructions MSN drug medications to stop selling a general version of the drug before the patent expires.
Entresto sales in the second quarter, increased by 22% in accordance with the previous three-month period.
“This short-term product is an important product for us,” the head finance officer Harry Kirsch, talked about Entresto on Thursday.
“We have the IP we have defended. We must be successful in defending our appeal, we will be a very important opposite every month,” he said.
In general, the net sales in the second quarter of Novartis increased by 11% to $ 14.05 billion on the basis of sustainable currency, approximately $ 14.18 billion in an LSEG in question.
Quarterly adjustable basic operating revenues increased to $ 2.93 billion for $ 2.93 billion in $ 2.93 billion.
Novartis has now increased the full annual basic operating revenues to raise the “lower teenagers” by “low double-digit” and maintained the forecast for sale in high single figures.
The company also announced a purchase of up to $ 10 billion by referring to “belief” to the average and long-term growth.
